Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Results from the PEACOCC trial warrant further investigation into treatment with pembrolizumab in patients with previously ...

Medical experts discuss approaches to patient education on managing potential adverse events associated with adagrasib and other KRAS-targeted therapies.

This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with KRAS+ non-small cell lung cancer as seen in clinical practice.

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

This video segment discusses strategies to help CAR-T therapy patients maintain quality of life, focusing on lifestyle ...

Erica S. Doubleday, MS, FNP-C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer. Monitoring patients’ symptoms across ...

Adolescent and young adult survivors of cancer face increased substance use risks due to developmental delays, limited ...

Dr Mohan discusses with Nurse Distaso and Dr Nadeem approaches to handling dose modifications or treatment interruptions due ...

Key opinion leaders explores the management of gastrointestinal side effects in patients on osimertinib, focusing on ...

This video segment explores the challenges of managing neurologic toxicities, including ICANS, in CAR-T therapy, highlighting ...

The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer ...